|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
512 2nd St, 4th Floor, San Francisco, California 94107, US
|
|
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Our lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. We are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. For more information about the company please visit www.olema.com.
Note: Olema will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview. Though we use third party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Olema.
|
Olema Oncology Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Olema Oncology email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Olema Oncology customer service number in your country click here to find.
Ruchi Dadlani is the CEO of Olema Oncology. To contact Ruchi Dadlani email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.